摘要
背景/目的:Prothymosin Alpha:(proTα)是1984年Haritos首先分离出的普遍存在的多肽,其作用仍然部分难以捉摸。我们知道proTα在细胞内作为一种抗凋亡和增殖介质和细胞外作为一种生物反应调节剂,类似于称为“报警器”的分子介导免疫反应。我们的研究团队率先阐明了proTα观察到的活性的机制。 结果:我们首次证明proTα水平在正常和异常细胞增殖期间增加。我们显示proTα多效作用,诱导对免疫细胞群的免疫调节作用。我们发现proTα的免疫反应区是羧基末端十肽proTα(100-109),两个分子都刺激先天免疫应答,通过Toll样受体(TLR),特别是TLR-4信号传导。我们报道proTα和proTα(100-109)在涉及TLR-4的位点上结合人嗜中性粒细胞的表面,细胞活化被细胞质钙离子流入补充。此外,我们显示proTα和proTα(100-109)作为淋巴细胞刺激上游的佐剂,并且在抗原存在下促进抗原反应性效应物的扩增。最近,我们报道proTα(100-109)可能在实验发炎部位积累,可以作为严重细菌感染的替代生物标志物,提出proTα或proTα(100-109)的细胞外释放在免疫系统的条件 危险。 结论:因此,我们建议proTα和可能的proTα(100-109)作为报警器,作为重要的免疫介质和生物标志物,并且最终可能成为免疫相关疾病如癌症,炎症中的新的治疗/诊断方法的靶标 和败血症。
关键词: Prothymosin alpha,proTα(100-109),惊厥症,癌症,炎症,败血症。
Current Medicinal Chemistry
Title:Prothymosin Alpha: An Alarmin and More...
Volume: 24 Issue: 17
关键词: Prothymosin alpha,proTα(100-109),惊厥症,癌症,炎症,败血症。
摘要: Background/Objective: Prothymosin alpha (proTα) is a ubiquitous polypeptide first isolated by Haritos in 1984, whose role still remains partly elusive. We know that proTα acts both, intracellularly, as an anti-apoptotic and proliferation mediator, and extracellularly, as a biologic response modifier mediating immune responses similarly to molecules termed as “alarmins”. Our research team pioneered the elucidation of the mechanisms underlying the observed activities of proTα.
Results: We were the first to demonstrate that proTα levels increase during normal and abnormal cell proliferation. We showed that proTα acts pleiotropically, inducing immunomodulatory effects on immune cell populations. We revealed that the immunoreactive region of proTα is the carboxyterminal decapeptide proTα(100-109) and both molecules stimulate innate immune responses, signaling through Toll-like receptors (TLRs), specifically TLR-4. We reported that proTα and proTα(100-109) bind on the surface of human neutrophils on sites involving TLR-4, and cell activation is complemented by cytoplasmic calcium ion influx. Further, we showed that proTα and proTα(100-109) act as adjuvants upstream of lymphocyte stimulation and, in the presence of antigen, promote the expansion of antigen-reactive effectors. Most recently, we reported that proTα(100-109) may accumulate in experimentally inflamed sites and can serve as a surrogate biomarker in severe bacterial infections, proposing that extracellular release of proTα or proTα(100- 109) alerts the immune system during conditions of danger. Conclusion: We, therefore, suggest that proTα, and likely proTα(100-109), act as alarmins, being important immune mediators as well as biomarkers, and could eventually become targets for new therapeutic/diagnostic approaches in immune-related diseases like cancer, inflammation, and sepsis.Export Options
About this article
Cite this article as:
Prothymosin Alpha: An Alarmin and More..., Current Medicinal Chemistry 2017; 24 (17) . https://dx.doi.org/10.2174/0929867324666170518110033
DOI https://dx.doi.org/10.2174/0929867324666170518110033 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ghrelin in Obesity, Physiological and Pharmacological Considerations
Mini-Reviews in Medicinal Chemistry Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design Combination Therapy of Cisplatin and other Agents for Osteosarcoma: A Review
Current Cancer Therapy Reviews A Novel Strategy for Preparing Glycopeptide Molecular Probe Using Fluorous Technology
Protein & Peptide Letters Editorial (Hot Topic: Ductal Carcinoma in situ (DCIS) of the Breast, Biomarkers, Diagnosis, and Treatment of the Disease)
Current Cancer Therapy Reviews Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Mechanism and Anticancer Activity of the Metabolites of an Endophytic Fungi from Eucommia ulmoides Oliv
Anti-Cancer Agents in Medicinal Chemistry Steroid Resistance in Severe Asthma: Current Mechanisms and Future Treatment
Current Pharmaceutical Design Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Gene Therapy for Pituitary Tumors
Current Gene Therapy Leukocyte P2 Receptors: A Novel Target for Anti-inflammatory and Antitumor Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds α7 Nicotinic Acetylcholine Receptor Subunit in Angiogenesis and Epithelial to Mesenchymal Transition
Current Drug Targets The Treatment of Autoimmune Hepatitis
Current Clinical Pharmacology Phosphoserine Aminotransferase has Conserved Active Site from Microbes to Higher Eukaryotes with Minor Deviations
Protein & Peptide Letters The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Recent Development in Nano-Sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs
Recent Patents on Anti-Cancer Drug Discovery Druggability of Mortalin for Cancer and Neuro-Degenerative Disorders
Current Pharmaceutical Design